<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00310882</url>
  </required_header>
  <id_info>
    <org_study_id>297-31.3-06-HMO-CTIL</org_study_id>
    <nct_id>NCT00310882</nct_id>
  </id_info>
  <brief_title>Involvement of Endogenous Digitalis-like Compounds in Breast Cancer</brief_title>
  <official_title>Involvement of Endogenous Digitalis-like Compounds in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The endogenous digitalis-like compounds (DLC)are steroid hormones synthesized and released&#xD;
      from the adrenal gland.They are integrated in the feed-back system of the&#xD;
      Hypothalami-Pituitary-Adrenal gland axis.One of their remarkable function is to induce&#xD;
      apoptosis in malignant cells. Recently, accumulating data point to the possibility of using&#xD;
      synthetic DLC as new anti-cancer drugs. Less is known about the endogenous metabolism of&#xD;
      these compounds in cancer patients.&#xD;
&#xD;
      Proceeding from preliminary clinical data which demonstrated significantly reduced DLC plasma&#xD;
      levels in breast cancer patients and from in vitro data which showed an impaired release of&#xD;
      DLC towards stress stimuli in athymic nude mice,we put up the hypothesis that a latent&#xD;
      adrenal insufficiency with low DLC levels facilitates the induction and progression of tumor&#xD;
      diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To pursue this question about endogenous DLC metabolism in cancer patients we intend to start&#xD;
      with the measurement of DLC plasma levels in breast cancer patients at the time of first&#xD;
      diagnosis and compare them to women with benign breast disease as well as healthy women.&#xD;
&#xD;
      Aim of the Study&#xD;
&#xD;
        -  To evaluate the basal DLC plasma concentrations in cancer patients at the time of first&#xD;
           diagnosis and the function of the HPA axis, with focussing on breast cancer patients.&#xD;
&#xD;
        -  To analyze a potential change of HPA function and, in parallel, DLC plasma&#xD;
           concentrations in the course of therapy, with special respect to treatment failure.&#xD;
&#xD;
        -  To establish a potential correlation between DLC plasma concentrations and risk factors&#xD;
           in BC.&#xD;
&#xD;
      Patients and Methods&#xD;
&#xD;
      Patients:&#xD;
&#xD;
      I. 50 - (100) patients with breast cancer at the time of first diagnosis&#xD;
&#xD;
      II. 50 - (100) patients with a benign disease of the breast&#xD;
&#xD;
      III. 50 - (100) women undergoing plastic surgery of the breast&#xD;
&#xD;
      IV. 50 - (100) women who need no further exploration after visit in ambulance (=normal&#xD;
      population)&#xD;
&#xD;
      V. additionally a group of 25 - 50 students (age 20-40) will be analyzed in a pilot study&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      Time-schedule for Group I (Group II. - IV. alike, according to disease and/or situation)&#xD;
&#xD;
        -  Day of first presentation of the woman at the clinic&#xD;
&#xD;
        -  Day of first diagnosis, i.e. biopsy/FNA&#xD;
&#xD;
        -  Day of start of treatment: operation, chemo-/radiotherapy (tst = 0)&#xD;
&#xD;
        -  Day + 30, + 60, + 90&#xD;
&#xD;
        -  6 month and 1 year after start of treatment&#xD;
&#xD;
      The Group V. (students) will be analyzed in a special schedule, preceding the study 1-2&#xD;
      months:&#xD;
&#xD;
        -  4 weeks before an important exam&#xD;
&#xD;
        -  a day before the exam (-3 days)&#xD;
&#xD;
        -  a day after the exam (+ 3 days)&#xD;
&#xD;
        -  2 weeks after the exam&#xD;
&#xD;
        -  6 weeks after the exam&#xD;
&#xD;
      Parameters&#xD;
&#xD;
      Biochemistry (Group I. - V.)&#xD;
&#xD;
        -  Basal DLC plasma concentration&#xD;
&#xD;
        -  Basal serum Cortisol concentration&#xD;
&#xD;
        -  Basal plasma ATCH concentration&#xD;
&#xD;
        -  Basal Aldosterone/Renin concentration&#xD;
&#xD;
        -  Electrolytes (potassium, sodium, calcium, chloride)&#xD;
&#xD;
      Pathology/Immunohistochemistry (Group I. + II., when benign, including last 4 points)&#xD;
&#xD;
        -  Tumor size&#xD;
&#xD;
        -  lymph node status&#xD;
&#xD;
        -  E/P receptors&#xD;
&#xD;
        -  Grade&#xD;
&#xD;
        -  HER2/neu&#xD;
&#xD;
        -  Bcl-2&#xD;
&#xD;
        -  Ki67&#xD;
&#xD;
        -  p53&#xD;
&#xD;
      Radiology (Group I.)&#xD;
&#xD;
      If abdominal CT available measurement of size of the adrenal glands&#xD;
&#xD;
      Endocrinologic tests (Group I. - IV.)&#xD;
&#xD;
        -  Dexamethasone-test (low dose):&#xD;
&#xD;
             -  2 mg Dexamethasone p.o. at 24:00&#xD;
&#xD;
             -  measurement of Cortisol and DLC at 8:00 the next morning&#xD;
&#xD;
        -  ACTH-test:&#xD;
&#xD;
             -  basal plasma concentrations of Cortisol, DLC and ACTH&#xD;
&#xD;
             -  administration of 250 µg ACTH (Synachten®) i.v.&#xD;
&#xD;
             -  measurement of Cortisol and DLC after 30 min. and 60 min.&#xD;
&#xD;
        -  Facultative: Metapyrone test&#xD;
&#xD;
      at following time intervals:&#xD;
&#xD;
        1. Dexamethasone-test&#xD;
&#xD;
             -  around the time of first presentation (± 5 days)&#xD;
&#xD;
             -  around the time of start of treatment (± 5 days); corresponding times for Group&#xD;
                II.- IV.&#xD;
&#xD;
             -  Day + 30, +60, +90&#xD;
&#xD;
             -  6 month and a year after start of treatment&#xD;
&#xD;
        2. ACTH-test&#xD;
&#xD;
             -  On the day of first presentation&#xD;
&#xD;
             -  On the day of start of treatment; corresponding times for Group II.- IV.&#xD;
&#xD;
             -  Day + 30, +60, +90&#xD;
&#xD;
             -  6 months and one year after start of treatment&#xD;
&#xD;
      Psychometric test for Stress Evaluation (Group I. - V.)&#xD;
&#xD;
        -  at the day of first presentation (Students: in between the last 2 weeks before an exam)&#xD;
&#xD;
        -  at the end of the study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    the PI is no longer work at Hadassah&#xD;
  </why_stopped>
  <start_date>May 2006</start_date>
  <completion_date type="Anticipated">May 2008</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Fibrocystic Disease of Breast</condition>
  <condition>Mammaplasty</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women with first diagnosis of Breast Cancer or a benign Breast Disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  first visit to a Breast Disease Ambulance for consultation&#xD;
&#xD;
          -  no pregnancy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  no severe heart disease (EF &gt; 40%)&#xD;
&#xD;
          -  no therapy with digitalis&#xD;
&#xD;
          -  no acute/chronic inflammatory disease (e.g. RA, M. Crohn)&#xD;
&#xD;
          -  no dysfunction of the Hypothalamo-Pituitary-Adrenal system&#xD;
&#xD;
          -  no severe mental disorder&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heidrun Weideman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Hebrew University Medical Centers</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hadassah Hebrew University Medical Centers</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <study_first_submitted>April 4, 2006</study_first_submitted>
  <study_first_submitted_qc>April 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2006</study_first_posted>
  <last_update_submitted>April 7, 2011</last_update_submitted>
  <last_update_submitted_qc>April 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Tanir Allweiss</name_title>
    <organization>Hadassah Medical Organization</organization>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>digitalis like compounds</keyword>
  <keyword>prognostic factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrocystic Breast Disease</mesh_term>
    <mesh_term>Breast Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

